David Young - Apr 11, 2023 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Role: President & CEO, Director, 10%+ Owner
Signature: /s/ David Young by Michael B. Kirwan, as Attorney-in-Fact
Stock symbol: PCSA
Transactions as of: Apr 11, 2023
Transactions value $: $29,000
Form type: 4
Date filed: 4/13/2023, 04:51 PM
Previous filing: Feb 10, 2023
Next filing: Apr 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCSA	Common Stock	Purchase	$10.4K	+20K	+5.71%	$0.52	370K	Apr 11, 2023	Direct	F1
transaction	PCSA	Common Stock	Purchase	$9K	+20K	+5.4%	$0.45	390K	Apr 12, 2023	Direct
transaction	PCSA	Common Stock	Purchase	$9.6K	+20K	+5.12%	$0.48	410K	Apr 13, 2023	Direct	F2
holding	PCSA	Common Stock						620K	Apr 11, 2023	By Young-Plaisance Revocable Trust
holding	PCSA	Common Stock						216K	Apr 11, 2023	By Family Entities
holding	PCSA	Common Stock						371K	Apr 11, 2023	By CorLyst, LLC

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.49 to $0.53, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.51, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Content

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.49 to $0.53, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.44 to $0.51, inclusive. The Reporting Person undertakes to provide Processa Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.